We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 177

Patent misuse in the pharmaceutical industry: developments in US & EU
  • Gowling WLG
  • European Union, USA
  • October 31 2007

The pharmaceutical industry has been scrutinised closely by competition authorities and courts in the US and Europe


Sanofi v ratiopharm, PMNOC Regulations decision irbesartan, March 5, 2010
  • Gowling WLG
  • Canada
  • May 21 2010

Sanofi sought an order prohibiting the granting of a NOC to ratiopharm


Patent validity - the Lords take a step in the right direction
  • Gowling WLG
  • United Kingdom
  • July 10 2008

The House of Lords has delivered a patent law decision which is likely to be welcomed by innovative companies throughout the UK and the pharmaceutical industry in particular


Apotex v. Sanofi; interlocutory motion re: affidavits of documents; clopidogrel
  • Gowling WLG
  • Canada
  • February 12 2010

Both parties brought motions for further and better affidavits of documents


Upstream without a paddle - Eli Lilly and Company v Human Genome Sciences Inc
  • Gowling WLG
  • United Kingdom
  • February 12 2010

Jacob LJ, giving his judgment for the Court of Appeal with which the other members of the court agreed, has upheld the decision of Kitchin J that the patent-in-suit was invalid for lack of industrial application


Pfizer v Ranbaxy; 55.2 proceeding; October 5, 2007 - atorvastatin
  • Gowling WLG
  • Canada
  • October 25 2007

The trial judge granted prohibition in respect of one patent claiming a novel crystalline form of atorvastatin (the "crystalline form patent") and denied prohibition in respect of another patent claiming a novel process for making atorvastatin (the "process patent"


Generics v Lundbeck - distinguishing the sufficiency requirements for product and process claims
  • Gowling WLG
  • United Kingdom
  • May 19 2008

In Generics v Lundbeck, the Court of Appeal provided important guidance on the judgment of the House of Lords in Biogen v Medeva regarding the scope of protection to which an inventor is entitled and the enabling disclosure the specification must provide to support the claims in the patent


Shire & Cephalon v. Apotex
  • Gowling WLG
  • Canada
  • May 8 2008

The Court dismissed the application on the basis that the allegation that the patent was invalid due to anticipation, obviousness and inutility was justified


PMPRB issues discussion paper on options to address the Federal Court decision in LEO Pharma
  • Gowling WLG
  • Canada
  • February 6 2008

The Patented Medicine Prices Review Board (PMPRB) has issued a discussion paper outlining a series of options to address the implications of the Federal Court of Canada decision in the LEO Pharma case


Federal court affirms standing for innovative drug manufacturer
  • Gowling WLG
  • Canada
  • July 23 2014

What rights do innovative drug manufacturers have in situations where generics challenge certain Health Canada decisions but do not name the